The use of SGLT2 inhibitors has been documented in studies such as DAPA-HF and EMPEROR-Reduced, where significant reductions in heart failure hospitalization risk (HR = 0.75 and HR = 0.70, respectively) were reported in patients with prior heart failure, as well as in patients with preserved or moderately reduced ejection fraction. This evidence concerns the gene SLC5A2 and hydrops fetalis.